FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

<b>STATEMENT</b>	OF CE	HANGES	IN RE	NEFICIA	I OWN	IFRSHIP
SIAILMENI	01 01	IANGES	IIA DE	.NEI ICIA	T CAAL	4 LIXOI III

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average to	ourden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Benatti Luca				Q	2. Issuer Name and Ticker or Trading Symbol Quince Therapeutics, Inc. [ QNCX ]								ck all applic Directo	onship of Reporting Pers Il applicable) Director Officer (give title		10% Ov	/ner	
(Last)	(F	irst)	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/05/2024							below)	(give title		Other (s below)	ресіту	
C/O QUINCE THERAPEUTICS, INC. 611 GATEWAY BLVD, SUITE 273			4.1	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	Individual or Joint/Group Filing (Check Applicable ne)  Form filed by One Reporting Person							
(Street) SOUTH FRANCI		A	94080	Ri	Rule 10b5-1(c) Transaction Indication								Form filed by More than One Reporting Person					
(City)	(S	tate)	(Zip)			Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.							to satisfy					
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date		Transaction Disposed Code (Instr. 5)		ties Acquired (A) or I Of (D) (Instr. 3, 4 and		5. Amour Securitie Beneficia Owned F Reported	Forn lly (D) o ollowing (I) (I		: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
						Code	v	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ction(s)		`				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, T Security or Exercise (Month/Day/Year) if any			ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (right to buy)	\$0.82	06/05/2024			A		27,000		06/05/2025	(1)	06/05/2034	Common Stock	27,000	\$0	27,000	0	D	

## **Explanation of Responses:**

1. 100% of the shares subject to this stock option will vest on the one-year anniversary of the grant date.

/s/ Brendan Hannah, Attorneyin-Fact for Luca Benatti

06/07/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.